Trial Profile
A Phase II Study of Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Primary endpoint has been met. (Objective clinical response rate)
- 02 Jun 2015 Status changed from recruiting to completed, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.